This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
Being a part of the stage of drug development where a molecule gets tested in people for the first time struck me as something I wanted to be a part of
Our holistic approach ensures that your physical, mental, and emotional well-being are addressed, empowering you to take control of your health and improve your quality of life
Despite the rapid adoption and growing claims experience, actuaries remain cautious about drawing conclusions from early data
